2022 American Transplant Congress
Clinical Outcomes In A Large Transplant Cohort Hospitalized With COVID-19: Mycophenolate Mofetil (MMF) Utilization And Mortality Trends
*Purpose: To characterize demographics, treatment patterns, and outcomes among 3,998 transplant patients hospitalized for COVID-19 over 16 months of the pandemic (May ’20-Aug ’21).*Methods: Adult…2022 American Transplant Congress
Effect of Mycophenolate Mofetil Dosing on Antibody Response to SARS-CoV-2 Vaccination in Heart and Lung Transplant Recipients
1Johns Hopkins University, Baltimore, MD, 2University of Wisconsin-Madison, Madison, WI
*Purpose: Mycophenolate mofetil (MMF) use is associated with decreased antibody response to the SARS-CoV-2 mRNA vaccine series in heart and lung transplant recipients (HLTRs). Higher…2022 American Transplant Congress
Immunosuppressants Alter Lymph Node Architecture and Create Distinct Microbiome Footprints
1University of Maryland School of Medicine, Baltimore, MD, 2University of Maryland, Baltimore, MD
*Purpose: There are complex interactions among immunosuppressants, antibiotics, and the gut microbiome on the host immune system. Microbiota can alter lymph node (LN) structure and…2022 American Transplant Congress
Reduced Enterohepatic Recirculation of Mycophenolate and Lower Blood Concentrations Are Associated with the Stool Bacterial Microbiome
*Purpose: Mycophenolate mofetil (MMF) is an important immunosuppressant used after allogeneic hematopoietic cell transplant (HCT). Blood concentrations of mycophenolic acid (MPA) are highly variable and…2022 American Transplant Congress
Use of Dd-cfdna to Guide Tapering of Immunosuppression Therapy in Kidney Transplant Recipients
1Victoria Kidney and Dialysis Associates, Victoria, TX, 2Natera, Inc., Austin, TX
*Purpose: Continuous administration of immunosuppressive therapy (IST) is required to avoid allograft rejection in transplant recipients. However, these therapeutic interventions can lead to significant side…2022 American Transplant Congress
Evaluating the Risk and Benefit of Once Daily Delayed Release Mycophenolate in Pediatric Kidney Transplant Recipients
*Purpose: Medication non-adherence continues to particularly affect adolescent kidney transplant recipients. Standard immunosuppressive regimen at our center includes tacrolimus, and mycophenolate with or without steroids.…2022 American Transplant Congress
Kidney Transplant Recipients with Diabetic Mellitus Demand Larger Doses of Mycophenolate Mofetil
Kidney transplant surgery and Urology, Sapporo City General Hospital, Sapporo, Japan
*Purpose: To monitor blood concentration of immunosuppressants, therapeutic drug monitoring (TDM) is required at any point after kidney transplantation (KT) to prevent kidney graft from…2022 American Transplant Congress
Assessing Proportion of Days Covered (PDC) of Mycophenolate (MCP) Prescriptions in Post Kidney Transplant (KT) Recipients as a Predictor of Clinical Outcomes
*Purpose: Nonadherence to medications following KT is a risk factor for adverse outcomes. PDC is an objective measure of adherence obtained through retail prescription records…2022 American Transplant Congress
Reduced Dose Mycophenolate Does Not Increase the Risk of Rejection Following Renal Transplantation
*Purpose: Mycophenolic acid (MPA) exposure correlates inversely with the risk of acute rejection; however, evidence also suggests that systemic MPA exposure also determines the extent…2022 American Transplant Congress
The Effect of Tacrolimus and Mycophenolic Acid on Torque Teno Virus Loads in Kidney Transplant Recipients
Leiden University Medical Center, Leiden, Netherlands
*Purpose: Measuring immune function in kidney transplant recipients (KTRs) remains challenging given the precarious balance between over- and underimmunosuppression. This is primarily due to high…
- 1
- 2
- 3
- …
- 6
- Next Page »